United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 7,061 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $121.12, for a total value of $855,228.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Corporation (UTHR) opened at $133.32 on Monday. The firm has a market capitalization of $5,760.89, a PE ratio of 11.76 and a beta of 1.42. United Therapeutics Corporation has a twelve month low of $112.01 and a twelve month high of $169.89.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $4.23 earnings per share. equities analysts expect that United Therapeutics Corporation will post 12.45 EPS for the current fiscal year.
UTHR has been the topic of several recent research reports. Zacks Investment Research upgraded United Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. HC Wainwright restated a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a research report on Thursday, October 26th. Cowen restated a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a research report on Friday, October 27th. Finally, Oppenheimer restated a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $136.10.
WARNING: “Martine A. Rothblatt Sells 7,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock” was posted by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://weekherald.com/2017/12/04/united-therapeutics-corporation-uthr-ceo-martine-a-rothblatt-sells-7061-shares-of-stock.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.